An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins

Abstract Tuberculosis is one the oldest known affliction of mankind caused by the pathogen Mycobacterium tuberculosis. Till date, there is no absolute single treatment available to deal with the pathogen, which has acquired a great potential to develop drug resistance rapidly. BCG is the only anti-t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rahul Sharma, Vikrant Singh Rajput, Salma Jamal, Abhinav Grover, Sonam Grover
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4972272220d14d9b852f63b1c28a10b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4972272220d14d9b852f63b1c28a10b5
record_format	dspace
spelling	oai:doaj.org-article:4972272220d14d9b852f63b1c28a10b52021-12-02T18:34:13ZAn immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins10.1038/s41598-021-93266-w2045-2322https://doaj.org/article/4972272220d14d9b852f63b1c28a10b52021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93266-whttps://doaj.org/toc/2045-2322Abstract Tuberculosis is one the oldest known affliction of mankind caused by the pathogen Mycobacterium tuberculosis. Till date, there is no absolute single treatment available to deal with the pathogen, which has acquired a great potential to develop drug resistance rapidly. BCG is the only anti-tuberculosis vaccine available till date which displays limited global efficacy due to genetic variation and concurrent pathogen infections. Extracellular vesicles or exosomes vesicle (EVs) lie at the frontier cellular talk between pathogen and the host, and therefore play a significant role in establishing pathogenesis. In the present study, an in-silico approach has been adopted to construct a multi-epitope vaccine from selected immunogenic EVs proteins to elicit a cellular as well as a humoral immune response. Our designed vaccine has wide population coverage and can effectively compensate for the genetic variation among different populations. For maximum efficacy and minimum adverse effects possibilities the antigenic, non-allergenic and non-toxic B-cell, HTL and CTL epitopes from experimentally proven EVs proteins were selected for the vaccine construct. TLR4 agonist RpfE served as an adjuvant for the vaccine construct. The vaccine construct structure was modelled, refined and docked on TLR4 immune receptor. The designed vaccine construct displayed safe usage and exhibits a high probability to elicit the critical immune regulators, like B cells, T-cells and memory cells as displayed by the in-silico immunization assays. Therefore, it can be further corroborated using in vitro and in vivo assays to fulfil the global need for a more efficacious anti-tuberculosis vaccine.Rahul SharmaVikrant Singh RajputSalma JamalAbhinav GroverSonam GroverNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rahul Sharma Vikrant Singh Rajput Salma Jamal Abhinav Grover Sonam Grover An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
description	Abstract Tuberculosis is one the oldest known affliction of mankind caused by the pathogen Mycobacterium tuberculosis. Till date, there is no absolute single treatment available to deal with the pathogen, which has acquired a great potential to develop drug resistance rapidly. BCG is the only anti-tuberculosis vaccine available till date which displays limited global efficacy due to genetic variation and concurrent pathogen infections. Extracellular vesicles or exosomes vesicle (EVs) lie at the frontier cellular talk between pathogen and the host, and therefore play a significant role in establishing pathogenesis. In the present study, an in-silico approach has been adopted to construct a multi-epitope vaccine from selected immunogenic EVs proteins to elicit a cellular as well as a humoral immune response. Our designed vaccine has wide population coverage and can effectively compensate for the genetic variation among different populations. For maximum efficacy and minimum adverse effects possibilities the antigenic, non-allergenic and non-toxic B-cell, HTL and CTL epitopes from experimentally proven EVs proteins were selected for the vaccine construct. TLR4 agonist RpfE served as an adjuvant for the vaccine construct. The vaccine construct structure was modelled, refined and docked on TLR4 immune receptor. The designed vaccine construct displayed safe usage and exhibits a high probability to elicit the critical immune regulators, like B cells, T-cells and memory cells as displayed by the in-silico immunization assays. Therefore, it can be further corroborated using in vitro and in vivo assays to fulfil the global need for a more efficacious anti-tuberculosis vaccine.
format	article
author	Rahul Sharma Vikrant Singh Rajput Salma Jamal Abhinav Grover Sonam Grover
author_facet	Rahul Sharma Vikrant Singh Rajput Salma Jamal Abhinav Grover Sonam Grover
author_sort	Rahul Sharma
title	An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
title_short	An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
title_full	An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
title_fullStr	An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
title_full_unstemmed	An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins
title_sort	immunoinformatics approach to design a multi-epitope vaccine against mycobacterium tuberculosis exploiting secreted exosome proteins
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4972272220d14d9b852f63b1c28a10b5
work_keys_str_mv	AT rahulsharma animmunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT vikrantsinghrajput animmunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT salmajamal animmunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT abhinavgrover animmunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT sonamgrover animmunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT rahulsharma immunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT vikrantsinghrajput immunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT salmajamal immunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT abhinavgrover immunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins AT sonamgrover immunoinformaticsapproachtodesignamultiepitopevaccineagainstmycobacteriumtuberculosisexploitingsecretedexosomeproteins
_version_	1718377857788411904

An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins

Ejemplares similares